Sherri Ann M Burnett-Bowie

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23
    Sherri Ann M Burnett-Bowie
    Endocrine Unit, Massachusetts General Hospital, Boston, USA
    Clin J Am Soc Nephrol 7:624-31. 2012
  2. pmc Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men
    Sherri Ann M Burnett-Bowie
    Endocrine Unit, Thier 1051, Massachusetts General Hospital, 50 Blossom Street, Boston, MA 02114, USA
    Bone 40:913-8. 2007
  3. doi request reprint Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates
    Sherri Ann M Burnett-Bowie
    Thier 1051, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 94:1097-103. 2009
  4. pmc Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men
    Sherri Ann M Burnett-Bowie
    Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Bone Miner Res 24:1681-5. 2009
  5. pmc Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels
    Sherri Ann M Burnett-Bowie
    Endocrine Unit, Massachusetts General Hospital, 50 Blossom Street, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 94:4785-92. 2009
  6. pmc Prevalence and predictors of vitamin D deficiency in healthy adults
    Deborah M Mitchell
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Endocr Pract 18:914-23. 2012
  7. pmc Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial
    Benjamin Z Leder
    Department of Medicine, Endocrine Unit B Z L, J N T, A V U, S A M B B, Y Z, K F, R M N and Biostatistics Center H L, Massachusetts General Hospital, Boston, Massachusetts 02114
    J Clin Endocrinol Metab 99:1694-700. 2014
  8. pmc Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
    Joy N Tsai
    Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA
    Lancet 382:50-6. 2013
  9. pmc Effects of teriparatide retreatment in osteoporotic men and women
    Joel S Finkelstein
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 94:2495-501. 2009
  10. ncbi request reprint Gonadal steroids and body composition, strength, and sexual function in men
    Joel S Finkelstein
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 369:1011-22. 2013

Research Grants

  1. Physiological regulation of FGF-23 by dietary phosphate
    SHERRI ANN BURNETT; Fiscal Year: 2004
  2. Dietary and hormonal regulation of FGF-23 in humans
    SHERRI ANN BURNETT BOWIE; Fiscal Year: 2007

Collaborators

Detail Information

Publications14

  1. pmc Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23
    Sherri Ann M Burnett-Bowie
    Endocrine Unit, Massachusetts General Hospital, Boston, USA
    Clin J Am Soc Nephrol 7:624-31. 2012
    ..The objective of this study was to determine the effect of ergocalciferol administration on fibroblast growth factor 23 levels in healthy vitamin D-deficient subjects...
  2. pmc Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men
    Sherri Ann M Burnett-Bowie
    Endocrine Unit, Thier 1051, Massachusetts General Hospital, 50 Blossom Street, Boston, MA 02114, USA
    Bone 40:913-8. 2007
    ..We examined if hypogonadism-induced increases in serum phosphate are associated with increases in circulating FGF-23 in healthy men in the absence of dietary manipulation...
  3. doi request reprint Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates
    Sherri Ann M Burnett-Bowie
    Thier 1051, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 94:1097-103. 2009
    ..The possibility of earlier indicators of a response or nonresponse to treatment, such as changes in bone turnover markers (BTMs), is of interest to physicians and patients...
  4. pmc Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men
    Sherri Ann M Burnett-Bowie
    Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Bone Miner Res 24:1681-5. 2009
    ..Given prior data that suggest that neither PTH nor calcium stimulate FGF23 secretion, these data support the assertion that 1,25(OH)(2)D is a potent physiologic stimulator of FGF23 secretion...
  5. pmc Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels
    Sherri Ann M Burnett-Bowie
    Endocrine Unit, Massachusetts General Hospital, 50 Blossom Street, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 94:4785-92. 2009
    ..Aging is associated with declining gonadal steroid production, low bone mineral density (BMD), and fragility fractures. The efficacy and safety of testosterone replacement in older men remains uncertain...
  6. pmc Prevalence and predictors of vitamin D deficiency in healthy adults
    Deborah M Mitchell
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Endocr Pract 18:914-23. 2012
    ..The goal of this study was to determine the prevalence and predictors of low 25-hydroxyvitamin D [25(OH)D] levels in healthy younger adults...
  7. pmc Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial
    Benjamin Z Leder
    Department of Medicine, Endocrine Unit B Z L, J N T, A V U, S A M B B, Y Z, K F, R M N and Biostatistics Center H L, Massachusetts General Hospital, Boston, Massachusetts 02114
    J Clin Endocrinol Metab 99:1694-700. 2014
    ..Attempts to improve efficacy by administering anabolic agents and bisphosphonates concomitantly have been unsuccessful. Conversely, 12 months of concomitant denosumab and teriparatide therapy increases BMD more than either drug alone...
  8. pmc Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
    Joy N Tsai
    Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA
    Lancet 382:50-6. 2013
    ..The combining of anabolic agents with bisphosphonates has not improved efficacy. We compared combined teriparatide and denosumab with both agents alone...
  9. pmc Effects of teriparatide retreatment in osteoporotic men and women
    Joel S Finkelstein
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 94:2495-501. 2009
    ..The stimulatory effect of teriparatide on bone mineral density (BMD) and bone turnover is initially exuberant, but then diminishes...
  10. ncbi request reprint Gonadal steroids and body composition, strength, and sexual function in men
    Joel S Finkelstein
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 369:1011-22. 2013
    ..Current approaches to diagnosing testosterone deficiency do not consider the physiological consequences of various testosterone levels or whether deficiencies of testosterone, estradiol, or both account for clinical manifestations...
  11. pmc Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis
    Benjamin Z Leder
    Endocrine Unit, THR 1047, Massachusetts General Hospital, 50 Blossom Street, Boston, MA 02114, USA
    J Clin Endocrinol Metab 94:2915-21. 2009
    ..In postmenopausal women, bone mineral density (BMD) declines after teriparatide therapy is stopped. The pattern of BMD loss after teriparatide therapy is stopped in men is less clear...
  12. pmc Clinical measures identify vitamin D deficiency in dialysis
    Ishir Bhan
    Department of Medicine, Massachusetts General Hospital, 50 Staniford Street, Suite 750, Boston, MA 02114, USA
    Clin J Am Soc Nephrol 5:460-7. 2010
    ..This study was conducted to determine whether routinely measured clinical and demographic parameters could identify dialysis patients who are vitamin D deficient...
  13. pmc The biology and pathology of vitamin D control in bone
    Taison D Bell
    Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Cell Biochem 111:7-13. 2010
    ..The active vitamin D metabolite has been shown to have both paracrine and endocrine actions in other tissues as well...
  14. ncbi request reprint An unusual case of primary hyperparathyroidism with profoundly elevated parathyroid hormone levels
    Allan F Moore
    Diabetes Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Endocr Pract 14:892-7. 2008
    ..To report the case of a man who presented with profoundly elevated parathyroid hormone levels in the setting of hypercalcemia, a palpable neck mass, renal disease, and metabolic bone disease...

Research Grants3

  1. Physiological regulation of FGF-23 by dietary phosphate
    SHERRI ANN BURNETT; Fiscal Year: 2004
    ..We anticipate that male and female participants will show different physiology. Finally, we anticipate that there will be a diurnal variation in FGF-23 that mirrors the diurnal variation in phosphate. ..
  2. Dietary and hormonal regulation of FGF-23 in humans
    SHERRI ANN BURNETT BOWIE; Fiscal Year: 2007
    ..The studies in this proposal will advance our understanding of the hormonal regulation of FGF-23 in humans and may help in the development of novel treatments for patients with hypo- or hyperphosphatemic disorders. ..